Advertisement
Advertisement
GANX
Gain Therapeutics, Inc. Common Stock
1.82
USDSponsored
-0.05
-2.67%
May 08, 15:58 UTC -4
Closed
After-Market
1.86
+0.04
+2.20%
GANX Earnings Reports
Positive Surprise Ratio
GANX beat 11 of 20 last estimates.
55%
Next Report
Date of Next Report
May 19, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.14
Implied change from Q4 25 (Revenue/ EPS)
--
/+27.27%
Implied change from Q1 25 (Revenue/ EPS)
--
/-12.50%
Gain Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 26, 2026, GANX reported earnings of -0.11 USD per share (EPS) for Q4 25, beating the estimate of -0.14 USD, resulting in a 25.63% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.63% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an increase of 27.27% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
FAQ
What were Gain Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Gain Therapeutics, Inc. Common Stock reported EPS of -$0.11, beating estimates by 25.63%, and revenue of $0.00, 0% as expectations.
How did the market react to Gain Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 2.63%, changed from $1.90 before the earnings release to $1.95 the day after.
When is Gain Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 19, 2026.
What are the forecasts for Gain Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Gain Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement